Judy Garber

Judy E. Garber, MD, MPH is the Director of the Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute, Attending physician at the Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School.

Her interests focus on breast cancer genetics, risk reduction and the development of therapeutics for the treatment and prevention of breast and related cancers in individuals carrying predisposing mutations. Her research includes the study of basal-like breast cancer, common in women with BRCA1 mutations. Her first neo-adjuvant trial of cisplatin in patients based on the role of BRCA1 in DNA repair demonstrated a significant complete response rate that has led to a series of trials, including a randomized phase II international, multicenter trial. Her research also includes the evaluation of novel agents targeting DNA repair defects in the treatment and prevention of triple negative or basal-like breast cancer, particularly platinums, PARP inhibitors and RANK ligand inhibitors.

Dr. Garber was elected to the National Academy of Medicine in 2013. She is a past president of the American Association for Cancer Research and a member of the National Cancer Advisory Board. She also served on the Board of Scientific Counselors of the National Cancer Institute. She has been a member of the BCRF Scientific Advisory Board since 2008.

Physician

• Chief, Division for Cancer Genetics and Prevention
• Susan F. Smith Chair
• Institute Physician
• Professor of Medicine, Harvard Medical School

Clinical Interests

• Breast cancer
• Cancer genetics
• Cancer prevention

Education

Medical School

• Yale University

Residency

• Brigham and Women's Hospital, 1981 - 1984

Board Certifications

• Internal Medicine, 1984
• Medical Oncology, 1987
• Hematology, 1988

Fellowships

• Brigham and Women's Hospital, 1984 - 1985
• Dana-Farber Cancer Institute, 1985 - 1988
• Dana-Farber Cancer Institute, 1989 - 1990

Awards

• Boston Magazine Top Doctor, 2021
• Castle Connolly America's Top Doctors, 2021